NCT00429091 - A Dose-Ranging Study of the Efficacy of ABT-894 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD) | Biotech Hunter

Enrollment

243

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

August 31, 2007

Conditions

Attention-Deficit/Hyperactivity DisorderADHD

Interventions

DRUG

ABT-894

Subjects will take 1 mg QD, 2 mg QD, 4 mg QD, 4 mg BID for up to four weeks.

DRUG

atomoxetine

Subjects will take 40 mg BID or placebo for up to four weeks.

DRUG

placebo

Subjects will take BID for up to four weeks

Trial Locations (22)

19149

Site Reference ID/Investigator# 5971, Philadelphia

20852

Site Reference ID/Investigator# 5952, Rockville

23452

Site Reference ID/Investigator# 5953, Virginia Beach

28211

Site Reference ID/Investigator# 5963, Charlotte

29407

Site Reference ID/Investigator# 5957, Charleston

32806

Site Reference ID/Investigator# 5974, Orlando

33407

Site Reference ID/Investigator# 5956, West Palm Beach

48085

Site Reference ID/Investigator# 5970, Troy

48864

Site Reference ID/Investigator# 5954, Okemos

60048

Site Reference ID/Investigator# 5973, Libertyville

66212

Site Reference ID/Investigator# 5968, Overland Park

77401

Site Reference ID/Investigator# 5959, Bellaire

78258

Site Reference ID/Investigator# 5969, San Antonio

78756

Site Reference ID/Investigator# 5972, Austin

84107

Site Reference ID/Investigator# 5951, Salt Lake City

92595

Site Reference ID/Investigator# 5955, Wildomar

97401

Site Reference ID/Investigator# 5975, Eugene

98007

Site Reference ID/Investigator# 5958, Bellevue

94143-0984

Site Reference ID/Investigator# 5965, San Francisco

02114

Site Reference ID/Investigator# 5962, Boston

08021

Site Reference ID/Investigator# 5960, Clementon

05401

Site Reference ID/Investigator# 5964, Burlington